Pfizer, Eli Lilly, Amgen and other pharmaceutical companies reported their first quarter earnings in the past week, according to a May 6 announcement. Pfizer exceeded consensus estimates but did not meet higher expectations set by analysts. In contrast, Eli Lilly saw a 56% increase in revenue, which analysts welcomed. However, company executives said they believed results could have been even stronger if not for recent price reductions on several medicines.
These quarterly reports are important because they provide insight into the financial health of major drugmakers and signal potential trends for the biotech industry. Analysts are also closely watching smaller biotechs as they begin to release their own results, focusing on upcoming catalysts that may impact future performance.
In regulatory news, the Food and Drug Administration appointed Katherine Szarama as acting director of the Center for Biologics Evaluation and Research (CBER) after Vinay Prasad's tenure ended on April 30. The agency also held its first advisory committee meeting in nine months to review two AstraZeneca cancer drug applications. Former regulator Harpreet Singh said this meeting lacked the “Pazdur moment,” referencing Richard Pazdur’s leadership before he left the agency last November.
There have been positive developments in research and development for amyotrophic lateral sclerosis (ALS), an area that has faced significant challenges recently. QurAlis reported that its candidate QRL-201 reduced disease progression by up to 50%, while Corcept Therapeutics announced a two-year survival advantage with its drug dazucorilant.
Additionally, senior BioSpace editor Annalee Armstrong interviewed biotech founders about current challenges facing those starting new companies.
